7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Ulrich-Vinther M et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. 2002 J Bone Joint Surg Am pmid:12177271
Ohmori H et al. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. 2002 J. Hum. Genet. pmid:12181640
Armstrong AP et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. 2002 J. Biol. Chem. pmid:12185073
Schoppet M et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. 2002 Arterioscler. Thromb. Vasc. Biol. pmid:11950689
Hasegawa T et al. Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. 2002 Tissue Cell pmid:11989970
Langdahl BL et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. 2002 J. Bone Miner. Res. pmid:12096838
Zhang J et al. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. 2002 J. Bone Miner. Res. pmid:12096839
Treuheit MJ et al. Inverse relationship of protein concentration and aggregation. 2002 Pharm. Res. pmid:12033388
Lossdörfer S et al. Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. 2002 Calcif. Tissue Int. pmid:12043011
Zhang J et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. 2002 FEBS Lett. pmid:12067713
Crotti TN et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. 2002 Ann. Rheum. Dis. pmid:12429533
Hofbauer LC and Schoppet M Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12432053
Jono S et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. 2002 Circulation pmid:12208791
Sedger LM et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. 2002 Eur. J. Immunol. pmid:12209637
Hofbauer LC et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. 2002 J. Cell. Biochem. pmid:12210731
Kondo H et al. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. 2002 J. Bone Miner. Res. pmid:12211438
Theill LE et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. 2002 Annu. Rev. Immunol. pmid:11861618
Roux S et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 2002 Am. J. Clin. Pathol. pmid:11863217
Green EA et al. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. 2002 Immunity pmid:11869680
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 J. Bone Miner. Res. pmid:11811549
Holloway WR et al. Leptin inhibits osteoclast generation. 2002 J. Bone Miner. Res. pmid:11811550
Coen G et al. Serum osteoprotegerin and renal osteodystrophy. 2002 Nephrol. Dial. Transplant. pmid:11812872
Woo KM et al. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. 2002 Exp. Mol. Med. pmid:12526098
Bengtsson AK and Ryan EJ Immune function of the decoy receptor osteoprotegerin. 2002 Crit. Rev. Immunol. pmid:12498383
Saidenberg Kermanac'h N et al. Osteoprotegerin and inflammation. 2002 Apr-Jun Eur. Cytokine Netw. pmid:12101070
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Younes A and Aggarwall BB Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. 2003 Cancer pmid:12879461
Liu JZ et al. [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product]. 2003 Zhonghua Wai Ke Za Zhi pmid:14680558
Nawroth P et al. [Osteoporosis and cardiovascular disease--two sides of the same coin?]. 2003 Med. Klin. (Munich) pmid:12928809
Yamada Y et al. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. 2003 Mol. Genet. Metab. pmid:14680982
Nakatsuka K et al. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. 2003 J. Bone Miner. Res. pmid:12929927
Li JP and Ling JQ [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. 2003 Zhonghua Kou Qiang Yi Xue Za Zhi pmid:12930661
Schett G et al. The role of osteoprotegerin in arthritis. 2003 Arthritis Res. Ther. pmid:12932284
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Karsdal MA et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. 2003 J. Biol. Chem. pmid:12933809
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Benevolenskaia LI [Issues of osteoporosis in present-day medicine]. 2003 Vestn. Akad. Med. Nauk SSSR pmid:12934464
Sugatani T et al. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. 2003 J. Cell. Biochem. pmid:12938156
Min JK et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 J. Biol. Chem. pmid:12893832
Teitelbaum SL and Ross FP Genetic regulation of osteoclast development and function. 2003 Nat. Rev. Genet. pmid:12897775
Hayashi S et al. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. 2003 J. Immunol. pmid:14607912
Padigel UM et al. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. 2003 J. Immunol. pmid:14607948
Gruber HE and Rude RK Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. 2003 Biotech Histochem pmid:14989640
Terpos E et al. New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 Br. J. Haematol. pmid:14632767
Ha H et al. Lipid rafts are important for the association of RANK and TRAF6. 2003 Exp. Mol. Med. pmid:14508068
Zhang L et al. The role of calmodulin in the regulation of osteoclastogenesis. 2003 Endocrinology pmid:12960067
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Boyan BD et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. 2003 Eur Cell Mater pmid:14577052
Zhang J et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. 2003 Cancer Res. pmid:14633717
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 Clin. Chem. pmid:14633883
Jung K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. 2003 J. Urol. pmid:14634401
Su X et al. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. 2003 Zhonghua Nei Ke Za Zhi pmid:14636471
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Cho TJ et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. 2003 Arthritis Rheum. pmid:14558090
von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. 2003 Eur J Gastroenterol Hepatol pmid:14560148
Barillé-Nion S and Bataille R New insights in myeloma-induced osteolysis. 2003 Leuk. Lymphoma pmid:14565645
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Garber K Why it hurts: researchers seek mechanisms of cancer pain. 2003 J. Natl. Cancer Inst. pmid:12783923
Liu B et al. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 J. Oral Pathol. Med. pmid:12787044
Eaton CL and Coleman RE Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. 2003 Cancer Treat. Rev. pmid:12787713
Fahrleitner-Pammer A et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 Wien. Klin. Wochenschr. pmid:12793029
Dovio A et al. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. 2003 Clin. Cancer Res. pmid:12796409
Flick LM et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. 2003 J. Orthop. Res. pmid:12798068
Khapli SM et al. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. 2003 J. Immunol. pmid:12816992
Kawase Y et al. Bone malformations in interleukin-18 transgenic mice. 2003 J. Bone Miner. Res. pmid:12817749
Kikuchi T et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. 2003 J. Dent. Res. pmid:12821717
D'Elia HF et al. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. 2003 Arthritis Res. Ther. pmid:12823855
Cheung J et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. 2003 J. Endocrinol. pmid:12773123
Nakamura H et al. Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. 2003 J. Med. Dent. Sci. pmid:12968638
Viereck V et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. 2003 J. Clin. Endocrinol. Metab. pmid:12970288
Yamagami H et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. 2003 Biochem. Pharmacol. pmid:12948861
Srivastava S et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. 2003 J. Biol. Chem. pmid:12952963
Lee HA et al. Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. 2003 Exp. Physiol. pmid:12955156
Yorke R et al. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. 2003 Eur. J. Cancer pmid:12957466
Kaneyama K et al. Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. 2003 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:12973279
Wong T et al. Therapeutic implications for interferon-alpha in arthritis: a pilot study. 2003 J. Rheumatol. pmid:12734885
Al-Qawasmi RA et al. Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. 2003 J. Dent. Res. pmid:12709501
Fujita D et al. Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12711253
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Rifas L et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 J. Cell. Biochem. pmid:12577299
Gordeladze JO and Reseland JE A unified model for the action of leptin on bone turnover. 2003 J. Cell. Biochem. pmid:12577304
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. 2003 J. Immunol. pmid:12594294
Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:12490655
Nishimura K et al. Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. 2003 Hum. Cell pmid:15147042
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Chagraoui H et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 Blood pmid:12506018
Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. 2003 J. Orthop. Res. pmid:12507581
Sabokbar A et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 J. Orthop. Res. pmid:12507582
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Crotti TN et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. 2003 J. Rheumatol. pmid:14677171
Sasaki T Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. 2003 Microsc. Res. Tech. pmid:12879416
Helfrich MH Osteoclast diseases. 2003 Microsc. Res. Tech. pmid:12879419

Table of Content